RETRACTED: Effect of intranasal oxytocin administration on psychiatric symptoms: A meta-analysis of placebo-controlled studies.
RETRACTED: Effect of intranasal oxytocin administration on psychiatric symptoms: A meta-analysis of placebo-controlled studies.
复制标题
DOI：
10.1016/j.psychres.2015.05.039
复制
发表时间：
2015-08-30
影响因子：
11.3
通讯作者：
Brager DN
中科院分区：
文献类型：
--
作者：
Hofmann SG;Fang A;Brager DN
鼻内注射催产素治疗精神疾病的临床试验结果喜忧参半。为了对鼻内给药催产素（OT）治疗精神症状的安慰剂对照临床试验进行定量评价，使用PubMed和PsycINFO进行手动和电子检索。在1，828个条目中，共有16项安慰剂对照研究，共计330名参与者被纳入分析。总体安慰剂对照效应量为中等强度（Hedges' g = 0.67），并且如故障安全N和漏斗图分析所示稳健。OT减少了抑郁症、焦虑症、自闭症/重复行为、精神病症状和一般精神病理学的症状。在合并样本中，症状减轻受给药频率调节。发表年份和诊断类别并没有缓和OT对临床结局指标的影响。我们得出结论，鼻内给药OT是一种潜在的有用的干预，以减少精神症状。然而，需要更多的研究来确定最佳治疗目标并确定治疗变化的机制。
Clinical trials of intranasal administration of oxytocin for treating psychiatric problems have yielded mixed results. To conduct a quantitative review of placebo-controlled clinical trials of intranasally-administered oxytocin (OT) for psychiatric symptoms, manual and electronic searches using PubMed and PsycINFO were conducted. Of 1,828 entries, 16 placebo-controlled studies totaling 330 participants were included in the analysis. The overall placebo-controlled effect size was moderately strong (Hedges’ g = 0.67) and robust as suggested by the fail-safe N and funnel plot analysis. OT reduced symptoms of depression, anxiety, autism/repetitive behaviors, psychotic symptoms, and general psychopathology. In the combined sample, symptom reduction was moderated by frequency of administration. Publication year and diagnostic category did not moderate the effect of OT on the clinical outcome measures. We conclude that intranasal administration of OT is a potentially useful intervention for reducing psychiatric symptoms. However, more studies are needed to determine the best treatment target and to identify the mechanism of treatment change.